Research graph
References from Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium
10.1002/cncr.23741 · 2008 · External reference
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
10.1016/s1470-2045(09)70025-7 · 2009 · External reference
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
10.1056/nejmoa043330 · 2005 · External reference
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers
10.1016/s1474-4422(10)70105-8 · 2010 · External reference
Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group
10.1200/jco.2009.26.3541 · 2010 · External reference
Current concepts and management of glioblastoma
10.1002/ana.22425 · 2011 · External reference
Evaluation of cancer therapy using diffusion magnetic resonance imaging
2003 · External reference
Neuroimaging in neuro-oncology
10.1016/j.nurt.2009.05.002 · 2009 · External reference
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects
10.1002/nbm.1611 · 2011 · External reference
Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma
10.3174/ajnr.a1750 · 2010 · External reference
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker
10.1158/1078-0432.ccr-04-1218 · 2004 · External reference
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma
10.1371/journal.pone.0035857 · 2012 · External reference
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors
10.1093/jnci/92.24.2029 · 2000 · External reference
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response
10.1073/pnas.0501532102 · 2005 · External reference
The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome
10.1593/neo.05844 · 2006 · External reference
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma
10.1073/pnas.0508347102 · 2005 · External reference
Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma
10.1038/sj.onc.1210455 · 2007 · External reference
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma
10.1371/journal.pone.0014545 · 2011 · External reference
Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity
10.1002/jmri.22068 · 2010 · External reference
10.1016/s1361-8415(97)85010-4 · 1997 · Admitted local publication
The parametric response map is an imaging biomarker for early cancer treatment outcome
10.1038/nm.1919 · 2009 · External reference
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma
10.1093/neuonc/nor220 · 2012 · External reference
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival
10.1200/jco.2007.15.2363 · 2008 · External reference
Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy
10.1016/j.ijrobp.2012.07.005 · 2013 · External reference
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging
1997 · External reference
Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration
10.1593/neo.122096 · 2012 · External reference
Dynamic imaging of emerging resistance during cancer therapy
10.1158/0008-5472.can-05-3205 · 2006 · External reference
Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps—initial observations
10.1148/radiol.10092469 · 2010 · External reference
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone
10.1593/neo.07954 · 2007 · External reference
Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology
10.1593/neo.111478 · 2012 · External reference
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone
10.1158/0008-5472.can-06-4236 · 2007 · External reference
